![Adel Nada](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Adel Nada is the founder of FytonBio, GentiBio, Inc. Current jobs include Independent Director at Alia Therapeutics Srl since 2023.
Former job includes Vice President-Immunotherapy at Caladrius Biosciences, Inc. Education includes a graduate degree from Rush University and a doctorate from Alexandria University.
| Unternehmen | Position | Beginn |
|---|---|---|
Alia Therapeutics Srl
 Alia Therapeutics Srl BiotechnologyHealth Technology Develops treatment of genetic diseases with genomic editing technology | Direktor/Vorstandsmitglied | 09.05.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
GentiBio, Inc.
 GentiBio, Inc. BiotechnologyHealth Technology Develops regulatory T-cells for allergic diseases | Vorstandsvorsitzender | - |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes cellular therapies products | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
Rush University
 Rush University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alexandria University
 Alexandria University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Caladrius Biosciences, Inc.
Caladrius Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes cellular therapies products | Health Technology |
Alia Therapeutics Srl
Alia Therapeutics Srl BiotechnologyHealth Technology Develops treatment of genetic diseases with genomic editing technology | Health Technology |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology Develops regulatory T-cells for allergic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
